<p>传奇生物公司（NASDAQ:LEGN - 获取免费报告）在周四创下 52 周新低，此前 Truist Financial 将该股的目标价从 88.00 美元下调至 71.00 美元。Truist Financial 目前对该股维持买入评级。传奇生物的股价最低曾达到 27.54 美元，最后交易价为 27.80 美元，成交量为 4184571 股。该股此前收盘价为 31.08 美元。</p>
<p>获取 <strong>传奇生物</strong> 的提醒：</p>
<ul>
<li>CPI 数据引发生物科技股反弹</li>
</ul>
<p>其他几家券商最近也对 LEGN 发布了报告。摩根士丹利将传奇生物的目标股价从 82.00 美元下调至 80.00 美元，并在 3 月 17 日的报告中给予该公司 “超配” 评级。加拿大皇家银行在 4 月 22 日的报告中重申了 “跑赢大盘” 评级，并对传奇生物的股票设定了 84.00 美元的目标价。Cantor Fitzgerald 在周三的报告中重新发布了 “超配” 评级，并对传奇生物的股票设定了 55.00 美元的目标价。Guggenheim 在 3 月 12 日的报告中重新发布了对传奇生物的 “中性” 评级。最后，HC Wainwright 在 4 月 16 日的报告中重新发布了 “买入” 评级，并对传奇生物的股票设定了 75.00 美元的目标价。一位投资分析师对该股给予了持有评级，十一位分析师给予了该公司股票买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “适度买入”，共识目标价为 74.73 美元。</p>
<p><strong>查看我们对 LEGN 的最新股票分析</strong></p>
<h2>机构投资者对传奇生物的看法</h2>
<ul>
<li>为什么传奇生物的股票正经历最佳月份</li>
</ul>
<p>对冲基金最近调整了对该公司的持股。Westfield Capital Management Co. LP 在第一季度将其在传奇生物的股份增加了 21.1%。Westfield Capital Management Co. LP 现在拥有 6917567 股该公司的股票，价值 234713000 美元，此前在上个季度购买了 1203871 股。Suvretta Capital Management LLC 在第四季度获得了传奇生物的新头寸，价值 113767000 美元。Invesco Ltd.在第四季度将其在传奇生物的股份增加了 44.7%。Invesco Ltd.现在拥有 3309971 股该公司的股票，价值 107706000 美元，此前在上个季度购买了 1022365 股。Braidwell LP 在第四季度将其在传奇生物的股份增加了 93.2%。Braidwell LP 现在拥有 2977951 股该公司的股票，价值 96903000 美元，此前在上个季度购买了 1436400 股。最后，马萨诸塞金融服务公司在第一季度将其在传奇生物的股份增加了 0.3%。马萨诸塞金融服务公司现在拥有 2270264 股该公司的股票，价值 77030000 美元，此前在上个季度购买了 6708 股。70.89% 的股票由机构投资者持有。</p>
<h2>传奇生物股票下跌 10.6%</h2>
<p>该公司的债务与股本比率为 0.27，流动比率为 4.98，速动比率为 4.90。该公司的 50 日简单移动平均为 33.79 美元，200 日简单移动平均为 36.09 美元。该股的市值为 51.1 亿美元，市盈率为-29.26，贝塔值为 0.20。</p>
<p>传奇生物（NASDAQ:LEGN - 获取免费报告）最近在 5 月 13 日发布了季度财报。该公司报告每股收益（EPS）为-0.07 美元，超出市场共识预期的-0.40 美元，超出幅度为 0.33 美元。传奇生物的股本回报率为-29.69%，净利润率为-66.92%。该公司在本季度的收入为 1.9505 亿美元，而分析师预期为 1.9083 亿美元。平均而言，卖方分析师预测传奇生物将在本财年发布-1.31 的每股收益。</p>
<h2>传奇生物公司简介</h2>
<p>（获取免费报告）</p>
<p>传奇生物公司是一家临床阶段的生物制药公司，通过其子公司从事新型细胞疗法的发现、开发、生产和商业化，主要用于肿瘤和其他适应症，业务覆盖美国、中国及国际市场。其主要产品候选药物 LCAR-B38M 是一种用于治疗多发性骨髓瘤（MM）的嵌合抗原受体。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是传奇生物</li>
<li>市值计算器：如何计算市值</li>
<li>SMCI 股票反弹：两天内上涨 45% 可能只是开始</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>AMD 的 AI 驱动股票价格反弹刚刚换挡</li>
<li>消费者价格指数测量什么？</li>
<li>5 只小盘股内部人士在关税恐慌高峰期买入</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在传奇生物吗？</h2>
<p>在考虑传奇生物之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而传奇生物并不在其中。</p>
<p>虽然传奇生物目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

传奇生物

<p>传奇生物（NASDAQ:LEGN）股价创下 52 周新低，达到 27.54 美元，此前 Truist Financial 将其目标价从 88 美元下调至 71 美元，但维持买入评级。该股收于 27.80 美元，跌幅为 10.6%。其他券商也调整了目标价，平均共识目标为 74.73 美元。公司报告的季度每股收益为（0.07 美元），超出预期，市值为 51.1 亿美元。传奇生物专注于开发肿瘤学领域的细胞疗法</p>

<p>Shares of Legend Biotech Co. (NASDAQ:LEGN - Get Free Report) reached a new 52-week low on Thursday after Truist Financial lowered their price target on the stock from $88.00 to $71.00. Truist Financial currently has a buy rating on the stock. Legend Biotech traded as low as $27.54 and last traded at $27.80, with a volume of 4184571 shares trading hands. The stock had previously closed at $31.08.</p>
<div class="lb-trans"><p>传奇生物公司（NASDAQ:LEGN - 获取免费报告）在周四创下 52 周新低，此前 Truist Financial 将该股的目标价从 88.00 美元下调至 71.00 美元。Truist Financial 目前对该股维持买入评级。传奇生物的股价最低曾达到 27.54 美元，最后交易价为 27.80 美元，成交量为 4184571 股。该股此前收盘价为 31.08 美元。</p>
</div><p>Get <strong>Legend Biotech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>传奇生物</strong> 的提醒：</p>
</div><ul>
<li>CPI Data Sparks Rally in Biotech Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>CPI 数据引发生物科技股反弹</li>
</ul>
</div><p>Several other brokerages also recently issued reports on LEGN. Morgan Stanley reduced their price target on shares of Legend Biotech from $82.00 to $80.00 and set an &#34;overweight&#34; rating for the company in a report on Monday, March 17th. Royal Bank of Canada reaffirmed an &#34;outperform&#34; rating and issued a $84.00 price objective on shares of Legend Biotech in a report on Tuesday, April 22nd. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $55.00 price target on shares of Legend Biotech in a report on Wednesday. Guggenheim reissued a &#34;neutral&#34; rating on shares of Legend Biotech in a report on Wednesday, March 12th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and issued a $75.00 price target on shares of Legend Biotech in a report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $74.73.</p>
<div class="lb-trans"><p>其他几家券商最近也对 LEGN 发布了报告。摩根士丹利将传奇生物的目标股价从 82.00 美元下调至 80.00 美元，并在 3 月 17 日的报告中给予该公司 “超配” 评级。加拿大皇家银行在 4 月 22 日的报告中重申了 “跑赢大盘” 评级，并对传奇生物的股票设定了 84.00 美元的目标价。Cantor Fitzgerald 在周三的报告中重新发布了 “超配” 评级，并对传奇生物的股票设定了 55.00 美元的目标价。Guggenheim 在 3 月 12 日的报告中重新发布了对传奇生物的 “中性” 评级。最后，HC Wainwright 在 4 月 16 日的报告中重新发布了 “买入” 评级，并对传奇生物的股票设定了 75.00 美元的目标价。一位投资分析师对该股给予了持有评级，十一位分析师给予了该公司股票买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “适度买入”，共识目标价为 74.73 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on LEGN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 LEGN 的最新股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Legend Biotech</h2>
<div class="lb-trans"><h2>机构投资者对传奇生物的看法</h2>
</div><ul>
<li>Why Legend Biotech Stock Is Having Its Best Month Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么传奇生物的股票正经历最佳月份</li>
</ul>
</div><p>Hedge funds have recently modified their holdings of the business. Westfield Capital Management Co. LP raised its stake in shares of Legend Biotech by 21.1% in the first quarter. Westfield Capital Management Co. LP now owns 6,917,567 shares of the company's stock valued at $234,713,000 after purchasing an additional 1,203,871 shares in the last quarter. Suvretta Capital Management LLC acquired a new position in shares of Legend Biotech in the fourth quarter valued at $113,767,000. Invesco Ltd. raised its stake in Legend Biotech by 44.7% during the fourth quarter. Invesco Ltd. now owns 3,309,971 shares of the company's stock worth $107,706,000 after acquiring an additional 1,022,365 shares in the last quarter. Braidwell LP raised its stake in Legend Biotech by 93.2% during the fourth quarter. Braidwell LP now owns 2,977,951 shares of the company's stock worth $96,903,000 after acquiring an additional 1,436,400 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Legend Biotech by 0.3% during the first quarter. Massachusetts Financial Services Co. MA now owns 2,270,264 shares of the company's stock worth $77,030,000 after acquiring an additional 6,708 shares in the last quarter. 70.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近调整了对该公司的持股。Westfield Capital Management Co. LP 在第一季度将其在传奇生物的股份增加了 21.1%。Westfield Capital Management Co. LP 现在拥有 6917567 股该公司的股票，价值 234713000 美元，此前在上个季度购买了 1203871 股。Suvretta Capital Management LLC 在第四季度获得了传奇生物的新头寸，价值 113767000 美元。Invesco Ltd.在第四季度将其在传奇生物的股份增加了 44.7%。Invesco Ltd.现在拥有 3309971 股该公司的股票，价值 107706000 美元，此前在上个季度购买了 1022365 股。Braidwell LP 在第四季度将其在传奇生物的股份增加了 93.2%。Braidwell LP 现在拥有 2977951 股该公司的股票，价值 96903000 美元，此前在上个季度购买了 1436400 股。最后，马萨诸塞金融服务公司在第一季度将其在传奇生物的股份增加了 0.3%。马萨诸塞金融服务公司现在拥有 2270264 股该公司的股票，价值 77030000 美元，此前在上个季度购买了 6708 股。70.89% 的股票由机构投资者持有。</p>
</div><h2>Legend Biotech Stock Down 10.6%</h2>
<div class="lb-trans"><h2>传奇生物股票下跌 10.6%</h2>
</div><p>The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. The firm has a 50 day simple moving average of $33.79 and a 200-day simple moving average of $36.09. The stock has a market capitalization of $5.11 billion, a price-to-earnings ratio of -29.26 and a beta of 0.20.</p>
<div class="lb-trans"><p>该公司的债务与股本比率为 0.27，流动比率为 4.98，速动比率为 4.90。该公司的 50 日简单移动平均为 33.79 美元，200 日简单移动平均为 36.09 美元。该股的市值为 51.1 亿美元，市盈率为-29.26，贝塔值为 0.20。</p>
</div><p>Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.33. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm had revenue of $195.05 million during the quarter, compared to analyst estimates of $190.83 million. On average, sell-side analysts forecast that Legend Biotech Co. will post -1.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>传奇生物（NASDAQ:LEGN - 获取免费报告）最近在 5 月 13 日发布了季度财报。该公司报告每股收益（EPS）为-0.07 美元，超出市场共识预期的-0.40 美元，超出幅度为 0.33 美元。传奇生物的股本回报率为-29.69%，净利润率为-66.92%。该公司在本季度的收入为 1.9505 亿美元，而分析师预期为 1.9083 亿美元。平均而言，卖方分析师预测传奇生物将在本财年发布-1.31 的每股收益。</p>
</div><h2>Legend Biotech Company Profile</h2>
<div class="lb-trans"><h2>传奇生物公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).</p>
<div class="lb-trans"><p>传奇生物公司是一家临床阶段的生物制药公司，通过其子公司从事新型细胞疗法的发现、开发、生产和商业化，主要用于肿瘤和其他适应症，业务覆盖美国、中国及国际市场。其主要产品候选药物 LCAR-B38M 是一种用于治疗多发性骨髓瘤（MM）的嵌合抗原受体。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Legend Biotech</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>AMD’s AI-Powered Stock Price Rally Just Shifted Gears</li>
<li>What does consumer price index measure?</li>
<li>5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是传奇生物</li>
<li>市值计算器：如何计算市值</li>
<li>SMCI 股票反弹：两天内上涨 45% 可能只是开始</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>AMD 的 AI 驱动股票价格反弹刚刚换挡</li>
<li>消费者价格指数测量什么？</li>
<li>5 只小盘股内部人士在关税恐慌高峰期买入</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Legend Biotech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在传奇生物吗？</h2>
</div><p>Before you consider Legend Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑传奇生物之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而传奇生物并不在其中。</p>
</div><p>While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然传奇生物目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

传奇生物（NASDAQ: LEGN）因分析师评级下调而创下 52 周新低